Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. Industriels
  2. Médicament
  3. EXELON (Rivastigmine (hydrogénotartrate))
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
  • Date 20 June 2007
  • Documents : 4
  • History
Listen Listen
Add to my selection
    Quote this publication
    Share
    Share on
    Facebook share - facebook.com - new window
    Tweeter share - Partager sur Twitter - twitter.com - new window
    LinkedIn share - linkedin.com - new window
    Print

    EXELON (Rivastigmine (hydrogénotartrate))

    Opinions on drugs - Posted on Oct 03 2007

    Reason for request

    Renouvellement d'inscription

    Documents

    • CT-3105 Xvox
    • Annexe 1 Xvox
    • Annexe 2 Xvox
    • Fiche BUM – Les médicaments de la maladie d’Alzheimer à visée symptomatique en pratique quotidienne Xvox

    Contact Us

    Évaluation des médicaments
    • Contact Us

    Follow us :

    • Twitter (nouvelle fenêtre)
    • Facebook (nouvelle fenêtre)
    • Youtube (nouvelle fenêtre)
    • LinkedIn (nouvelle fenêtre)
    Haute Autorité de Santé
    Advancing quality in the fields of health and social care services
    • Eunetha.eu
    • Pasq.eu
    • All our publications by topic and type
    • Opinions on medicines
    • Opinions on medical devices
    • INAHTA briefs
    • Français
    • English
    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
    qmEKCNL54sqDFU9U